RECORD // Company

Tvardi Therapeutics, Inc.

Formerly: Cara Therapeutics, Inc.; Cara Therapeutics Inc

Built 2026-11-21T00:09:39Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (5)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

Matched by name only, not merged (3)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Tvardi Therapeutics, Inc · Ctgov · same registered legal name as 'Tvardi Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Tvardi Therapeutics, Incorporated · Ctgov · same registered legal name as 'Tvardi Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • TVARDI THERAPEUTICS, INC. · East licences · same registered legal name as 'Tvardi Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001104659-26-126508

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-6,124,0003 months ended 2026-09-3010-Q2026-11-130001104659-26-1265082026-11-21 00:09 UTCReport an error
Cash and cash equivalents$22,275,000at 2026-09-3010-Q2026-11-130001104659-26-1265082026-11-21 00:09 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001346830
Ticker
TVRD
Record ID
sx:sec:0001346830

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

23 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-19SEC EDGAR company profile2026-11-21 00:09 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-19SEC EDGAR company profile2026-11-21 00:09 UTCReport an error
State of incorporationDE2026-11-19SEC EDGAR company profile2026-11-21 00:09 UTCReport an error
Fiscal year end (MMDD)12312026-11-19SEC EDGAR company profile2026-11-21 00:09 UTCReport an error
Business address3 SUGAR CREEK CTR. BLVD., STE 525, SUGAR LAND, TX, 774782026-11-19SEC EDGAR company profile2026-11-21 00:09 UTCReport an error
ExchangesNasdaq2026-11-19SEC EDGAR company profile2026-11-21 00:09 UTCReport an error
Revenue (fiscal year ended 2024-12-31)$7,137,0002024-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 00:09 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-18,214,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 00:09 UTCReport an error
Total assets (at 2025-12-31)$32,073,0002025-12-3110-K, XBRL Assets2026-11-21 00:09 UTCReport an error
Stockholders' equity (at 2025-12-31)$20,946,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 00:09 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$20,734,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 00:09 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-23,499,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 00:09 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2024-12-31)$1,046,0002024-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 00:09 UTCReport an error
Operating lease liabilities (at 2025-12-31)$201,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 00:09 UTCReport an error
Form D total offering amount (D filed 2014-12-11)$100,0032014-12-11D2026-11-21 00:09 UTCReport an error
Form D total amount sold (D filed 2014-12-11)$100,0032014-12-11D2026-11-21 00:09 UTCReport an error
Form D industry groupBiotechnology2014-12-11D2026-11-21 00:09 UTCReport an error
Form D revenue range$5,000,001 - $25,000,0002014-12-11D2026-11-21 00:09 UTCReport an error
Form D date of first sale2014-12-012014-12-11D2026-11-21 00:09 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-19)On November 19, 2026, Tvardi Therapeutics, Inc. (the "Company") issued a press release entitled "Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback." The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be…2026-11-19SEC EDGAR 8-K 0001104659-26-129948 (text as filed, excerpt)2026-11-21 00:09 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-13)On November 13, 2026, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter ended September 30, 2026. A copy of the Company’s press release dated November 13, 2026 is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained herein and the accompanying Exhibit 99.1 is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act…2026-11-13SEC EDGAR 8-K 0001104659-26-126507 (text as filed, excerpt)2026-11-21 00:09 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-14)On August 14, 2026, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter ended June 30, 2026. A copy of the Company’s press release dated August 14, 2026 is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information contained herein and the accompanying Exhibit 99.1 is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933…2026-08-14SEC EDGAR 8-K 0001104659-26-096417 (text as filed, excerpt)2026-11-21 00:09 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-07-30)On July 30, 2026, Tvardi Therapeutics, Inc. (the "Company") issued a press release entitled "Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109." The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. On July 30, 2026, the Company also made available an updated corporate presentation. A copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibits 99.1 and 99.2) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange…2026-07-30SEC EDGAR 8-K 0001104659-26-088461 (text as filed, excerpt)2026-11-21 00:09 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.